Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

Conditions: Lung Diseases, Interstitial

First Posted Date: 2019-02-18

Last Posted Date: 2024-12-10

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT03843892

Locations: 🇺🇸
Banner University Medical Center Tucson, Tucson, Arizona, United States
🇺🇸
The Lung Research Center, LLC, Chesterfield, Missouri, United States
🇺🇸
Glacier View Research Institute, Kalispell, Montana, United States

and more 3 locations

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Phase 1

Completed

Conditions: Healthy
Hepatic Insufficiency

Interventions: Drug: BI 685509
Drug: Placebo

First Posted Date: 2019-02-15

Last Posted Date: 2021-06-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT03842761

Locations: 🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894
Drug: Itraconazole

First Posted Date: 2019-02-15

Last Posted Date: 2021-11-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03843151

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583

First Posted Date: 2019-02-12

Last Posted Date: 2021-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT03837964

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Phase 2

Terminated

Conditions: Psoriasis

Interventions: Drug: BI 730357
Drug: Placebo to match BI 730357

First Posted Date: 2019-02-08

Last Posted Date: 2022-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 165

Registration Number: NCT03835481

Locations: 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸
Southern California Dermatology Inc., Santa Ana, California, United States

and more 26 locations

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Phase 2

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: Placebo
Drug: BI 655130

First Posted Date: 2019-01-30

Last Posted Date: 2022-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 51

Registration Number: NCT03822832

Locations: 🇺🇸
Center for Dermatology and Plastic Surgery, Scottsdale, Arizona, United States
🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
ForCare Clinical Research, Inc., Tampa, Florida, United States

and more 20 locations

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Phase 3

Completed

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2019-01-29

Last Posted Date: 2023-09-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 435

Registration Number: NCT03820726

Locations: 🇯🇵
National Hospital Organization Himeji Medical Center, Hyogo, Himeji, Japan
🇫🇷
HOP Civil, Strasbourg, France
🇷🇺
1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., St. Petersburg, Russian Federation

and more 118 locations

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809 (Treatment T1)
Drug: BI 425809 (Treatment T2)
Drug: BI 425809 (Treatment R)

First Posted Date: 2019-01-25

Last Posted Date: 2019-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT03817476

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

First Posted Date: 2019-01-25

Last Posted Date: 2022-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 171808

Registration Number: NCT03817463

Locations: 🇯🇵
Gifu University, Gifu, Japan
🇩🇰
Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology, Gentofte, Denmark
🇩🇪
University of Ulm, Institute for Epidemiology and medical biometry, Ulm, Germany

and more 10 locations

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Sodium Glucose Transporter 2 inhibitor
Drug: Dipeptidyl-peptidase 4 inhibitor
Drug: Glucagon-like peptide 1 agonist

First Posted Date: 2019-01-17

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4083

Registration Number: NCT03807440

Locations: 🇷🇺
Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095, Penza, Russian Federation
🇧🇬
MC "Diamedical 2013" OOD, Center Nr.: 35902, Dimitrovgrad, Bulgaria
🇧🇬
"Medical Center-Razgrad"OOD, Center Nr.: 35910, Razgrad, Bulgaria

and more 174 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy